This paper considers whether individual companies have an ethical obligation to label their Genetically Modified (GM) foods. GM foods and ingredients pervade grocery store shelves, despite the fact that a majority of North Americans have worries about eating those products. The market as whole has largely failed to respond to consumer preference in this regard, as have North American governments. A number of consumer groups, NGO’s, and activist organizations have urged corporations to label their GM products. This paper asks whether, (...) in such a situation, individual corporations can be ethically required to take such unilateral action. We argue that they cannot. Given the lack of solid evidence for any risk to human health, and the serious market disadvantage almost surely associated with costly unilateral action, no individual company has an ethical obligation to label its GM foods. (shrink)

This paper looks at some of the ethical concerns regarding a recent application to the U.S. Food and Drug Administration for approval of the sale of HIV tests over-the-counter directly to consumers. The concept of at-home HIV testing is not new, but OraSure Technologies Inc., a U.S. manufacturer of rapid HIV tests, is now seeking FDA approval to take at-home testing one step further to enable consumers to test themselves and interpret the results without the assistance of an outside party. (...) This paper reviews some of the purported benefits and potential risks of at-home HIV testing, and looks at the way one Canadian company is attempting to address the potential risks. In doing so, this paper brings to the fore concerns regarding corporate involvement in the regulatory approval of biotech products. (shrink)

This paper looks at some of the ethical concerns regarding a recent application to the U.S. Food and Drug Administration (FDA) for approval of the sale of HIV tests over-the-counter (OTC) directly to consumers. The concept of at-home HIV testing is not new, but OraSure Technologies Inc., a U.S. manufacturer of rapid HIV tests, is now seeking FDA approval to take at-home testing one step further to enable consumers to test themselves and interpret the results without the assistance of an (...) outside party. This paper reviews some of the purported benefits and potential risks of at-home HIV testing, and looks at the way one Canadian company is attempting to address the potential risks. In doing so, this paper brings to the fore concerns regarding corporate involvement in the regulatory approval of biotech products. (shrink)